The last time I wrote about Abbott Laboratories (ABT) I stated, "Due to the bearish technicals, falling financial efficiency ratios, and reduced 2015 earnings estimates, I will not be adding to my position right here." Since writing the article, the stock has increased 6.75% versus the 6.12% gain the S&P 500 (SPY) posted. Abbott is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based healthcare products, which operates in four segments: Diagnostics, Medical Devices, Nutritionals and Generic Pharmaceuticals.
On April 16, 2014, the company reported first quarter earnings of $0.41 per share, which beat the consensus of analysts' estimates by $0.05. In the past year, the company's stock is up 20.1% excluding dividends (up 22.05% including dividends) and is losing to the S&P 500, which has gained 23.6% in the same time frame. Since initiating my position back on May 28, 2013, I'm up 15.07% inclusive